FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094863418> ?p ?o ?g. }

• W2094863418 endingPage "e2611" @default.
• W2094863418 startingPage "e2611" @default.
• W2094863418 abstract "Background The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India—an area highly endemic for Leishmania donovani—in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL. Methods and Principal Findings Over a 5-year period, Ambisome was administered to 8749 patients with laboratory-confirmed VL (clinical signs, rK39 positive, with/without parasite confirmation) in four intravenous doses of 5 mg/kg to a total of 20 mg/kg, with a high initial-cure rate (99.3%) and low default rate (0.3%). All patients received health education highlighting the possibility and symptoms of developing PKDL, and advice to return to the MSF programme if these symptoms developed. This is an observational retrospective cohort study of the programme outcomes. Of the 8311 patients completing treatment for their first episode of VL, 24 (0.3%) returned passively to the programme complaining of symptoms subsequently confirmed as PKDL, diagnosed from clinical history, appearance consistent with PKDL, and slit-skin smear examination. Of the 24 patients, 89% had macular lesions, with a median time (interquartile range) to development of 1.2 (0.8–2.2) years following treatment. Comparison of the demographic and clinical characteristics of the VL patients treated with Ambisome who later developed PKDL, with those of the remaining cohort did not identify any significant risk factors for PKDL. However, the time to developing PKDL was significantly shorter with Ambisome than in a subset of patients presenting to the programme with PKDL following previous sodium stibogluconate treatment for VL. Conclusions In this large cohort of patients with VL in Bihar who were treated with 20 mg/kg Ambisome, PKDL following treatment appears to be infrequent with no predictive risk factors. The shorter median time to developing symptoms of PKDL compared with that after conventional VL treatments should be taken into account when counseling patients treated with regimens including Ambisome." @default.
• W2094863418 created "2016-06-24" @default.
• W2094863418 creator A5001974190 @default.
• W2094863418 creator A5027589913 @default.
• W2094863418 creator A5037338010 @default.
• W2094863418 creator A5039960692 @default.
• W2094863418 creator A5071004834 @default.
• W2094863418 creator A5074357118 @default.
• W2094863418 creator A5083176889 @default.
• W2094863418 creator A5086314663 @default.
• W2094863418 date "2014-01-02" @default.
• W2094863418 modified "2023-10-18" @default.
• W2094863418 title "Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India" @default.
• W2094863418 cites W1572040302 @default.
• W2094863418 cites W1622923672 @default.
• W2094863418 cites W1825928607 @default.
• W2094863418 cites W1848585049 @default.
• W2094863418 cites W1976469493 @default.
• W2094863418 cites W1981711656 @default.
• W2094863418 cites W2020830292 @default.
• W2094863418 cites W2030364077 @default.
• W2094863418 cites W2052187913 @default.
• W2094863418 cites W2057498107 @default.
• W2094863418 cites W2058318327 @default.
• W2094863418 cites W2066732010 @default.
• W2094863418 cites W2094091054 @default.
• W2094863418 cites W2144756920 @default.
• W2094863418 cites W4251061685 @default.
• W2094863418 doi "https://doi.org/10.1371/journal.pntd.0002611" @default.
• W2094863418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3879248" @default.
• W2094863418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24392171" @default.
• W2094863418 hasPublicationYear "2014" @default.
• W2094863418 type Work @default.
• W2094863418 sameAs 2094863418 @default.
• W2094863418 citedByCount "32" @default.
• W2094863418 countsByYear W20948634182014 @default.
• W2094863418 countsByYear W20948634182015 @default.
• W2094863418 countsByYear W20948634182016 @default.
• W2094863418 countsByYear W20948634182017 @default.
• W2094863418 countsByYear W20948634182018 @default.
• W2094863418 countsByYear W20948634182019 @default.
• W2094863418 countsByYear W20948634182020 @default.
• W2094863418 countsByYear W20948634182021 @default.
• W2094863418 countsByYear W20948634182022 @default.
• W2094863418 countsByYear W20948634182023 @default.
• W2094863418 crossrefType "journal-article" @default.
• W2094863418 hasAuthorship W2094863418A5001974190 @default.
• W2094863418 hasAuthorship W2094863418A5027589913 @default.
• W2094863418 hasAuthorship W2094863418A5037338010 @default.
• W2094863418 hasAuthorship W2094863418A5039960692 @default.
• W2094863418 hasAuthorship W2094863418A5071004834 @default.
• W2094863418 hasAuthorship W2094863418A5074357118 @default.
• W2094863418 hasAuthorship W2094863418A5083176889 @default.
• W2094863418 hasAuthorship W2094863418A5086314663 @default.
• W2094863418 hasBestOaLocation W20948634181 @default.
• W2094863418 hasConcept C126322002 @default.
• W2094863418 hasConcept C141071460 @default.
• W2094863418 hasConcept C16005928 @default.
• W2094863418 hasConcept C203014093 @default.
• W2094863418 hasConcept C2776555147 @default.
• W2094863418 hasConcept C2778689377 @default.
• W2094863418 hasConcept C2779548794 @default.
• W2094863418 hasConcept C2779629538 @default.
• W2094863418 hasConcept C2780122544 @default.
• W2094863418 hasConcept C2781333301 @default.
• W2094863418 hasConcept C71924100 @default.
• W2094863418 hasConceptScore W2094863418C126322002 @default.
• W2094863418 hasConceptScore W2094863418C141071460 @default.
• W2094863418 hasConceptScore W2094863418C16005928 @default.
• W2094863418 hasConceptScore W2094863418C203014093 @default.
• W2094863418 hasConceptScore W2094863418C2776555147 @default.
• W2094863418 hasConceptScore W2094863418C2778689377 @default.
• W2094863418 hasConceptScore W2094863418C2779548794 @default.
• W2094863418 hasConceptScore W2094863418C2779629538 @default.
• W2094863418 hasConceptScore W2094863418C2780122544 @default.
• W2094863418 hasConceptScore W2094863418C2781333301 @default.
• W2094863418 hasConceptScore W2094863418C71924100 @default.
• W2094863418 hasIssue "1" @default.
• W2094863418 hasLocation W20948634181 @default.
• W2094863418 hasLocation W20948634182 @default.
• W2094863418 hasLocation W20948634183 @default.
• W2094863418 hasLocation W20948634184 @default.
• W2094863418 hasOpenAccess W2094863418 @default.
• W2094863418 hasPrimaryLocation W20948634181 @default.
• W2094863418 hasRelatedWork W103991714 @default.
• W2094863418 hasRelatedWork W2052790123 @default.
• W2094863418 hasRelatedWork W2063640241 @default.
• W2094863418 hasRelatedWork W2067709645 @default.
• W2094863418 hasRelatedWork W2189323167 @default.
• W2094863418 hasRelatedWork W2315822332 @default.
• W2094863418 hasRelatedWork W2418689966 @default.
• W2094863418 hasRelatedWork W2619600656 @default.
• W2094863418 hasRelatedWork W4212976809 @default.
• W2094863418 hasRelatedWork W4293071197 @default.
• W2094863418 hasVolume "8" @default.
• W2094863418 isParatext "false" @default.
• W2094863418 isRetracted "false" @default.
• W2094863418 magId "2094863418" @default.

• next